These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 2590999)
21. In vivo modulation of several anticancer agents by beta-carotene. Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757 [TBL] [Abstract][Full Text] [Related]
22. Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Eder JP; Teicher BA; Holden SA; Senator L; Cathcart KN; Schnipper LE Cancer Chemother Pharmacol; 1990; 26(6):423-8. PubMed ID: 2171796 [TBL] [Abstract][Full Text] [Related]
23. Lonidamine can enhance the cytotoxic effect of cisplatin in human tumour cells and rodent cells. Raaphorst GP; Feeley MM; Heller DP; Danjoux CE; Martin L; Maroun JA; De Sanctis AJ Anticancer Res; 1990; 10(4):923-7. PubMed ID: 2382989 [TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro. Ning SC; Hahn GM Cancer Res; 1990 Dec; 50(24):7867-70. PubMed ID: 2253227 [TBL] [Abstract][Full Text] [Related]
25. In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line. Roncuzzi L; Zoli W; Bajorko P; Gasperi-Campani A Anticancer Res; 1995; 15(3):773-6. PubMed ID: 7645957 [TBL] [Abstract][Full Text] [Related]
26. The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines. Ko D; Raaphorst GP; Feeley MM; Danjoux CE; Maroun JA; Evans WK Anticancer Res; 1991; 11(1):235-9. PubMed ID: 1850216 [TBL] [Abstract][Full Text] [Related]
27. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE J Clin Invest; 1987 May; 79(5):1524-8. PubMed ID: 3033027 [TBL] [Abstract][Full Text] [Related]
28. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Chen G; Waxman DJ Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907 [TBL] [Abstract][Full Text] [Related]
29. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474 [TBL] [Abstract][Full Text] [Related]
30. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968 [TBL] [Abstract][Full Text] [Related]
31. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236 [TBL] [Abstract][Full Text] [Related]
32. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Perez EA; Hack FM; Webber LM; Chou TC Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606 [TBL] [Abstract][Full Text] [Related]
33. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Lidor YJ; Shpall EJ; Peters WP; Bast RC Int J Cancer; 1991 Nov; 49(5):704-10. PubMed ID: 1937956 [TBL] [Abstract][Full Text] [Related]
34. Morphological effects of lonidamine on two human-tumor cell culture lines. Szekely JG; Lobreau AU; Delaney S; Raaphorst GP; Feeley M Scanning Microsc; 1989 Jun; 3(2):681-91; discussion 691-3. PubMed ID: 2814409 [TBL] [Abstract][Full Text] [Related]
35. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. Smith KS; Folz BA; Adams EG; Bhuyan BK Cancer Chemother Pharmacol; 1995; 35(6):471-82. PubMed ID: 7533669 [TBL] [Abstract][Full Text] [Related]
36. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747 [TBL] [Abstract][Full Text] [Related]
37. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Villa R; Orlandi L; Berruti A; Dogliotti L; Zaffaroni N Int J Oncol; 1999 Jan; 14(1):133-8. PubMed ID: 9863019 [TBL] [Abstract][Full Text] [Related]
38. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Cheng MF; Chatterjee S; Berger NA Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902 [TBL] [Abstract][Full Text] [Related]
39. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129 [TBL] [Abstract][Full Text] [Related]
40. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]